A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Study of JNJ-78278343 in Patients with Advanced Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAT8831
U.S. Govt. ID: NCT04898634
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a safe dose of JNJ-78278343 that can be used in the treatment of prostate cancer. To do this, we must find out if JNJ-78278343 can cause side-effects. Also, we need to find out how long JNJ-78278343 stays in and acts on your body and how your body responds to it. Prostate cancer is known to have high levels of a protein called KLK2 or hK2. KLK2 is a protein responsible for activating prostate-specific antigen (PSA) which in higher levels can indicate the presence of prostate cancer. hK2 is a protein responsible for the production of glucose-6-phosphate which is used in the metabolism of glucose. JNJ-78278343 is an antibody-like drug that is designed to attach to your T cells (a type of white blood cells in your immune system) and also to KLK2 on your cancer cells. JNJ-78278343 attaches to both of these in order to bring them closer together, starting the killing of the cancer cells by your body's own T cells. JNJ-78278343 has been studied in test tubes and in animals only. This is the first time that JNJ-78278343 is tested in humans.
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with prostate cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator